MENU
+Compare
EXEL
Stock ticker: NASDAQ
AS OF
Sep 16, 01:35 PM (EDT)
Price
$38.93
Change
-$0.08 (-0.21%)
Capitalization
10.5B

EXEL Exelixis Forecast, Technical & Fundamental Analysis

Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer... Show more

Industry: #Biotechnology
EXEL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
a Summary for EXEL with price predictions
Sep 15, 2025

Momentum Indicator for EXEL turns positive, indicating new upward trend

EXEL saw its Momentum Indicator move above the 0 level on September 11, 2025. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 88 similar instances where the indicator turned positive. In of the 88 cases, the stock moved higher in the following days. The odds of a move higher are at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Moving Average Convergence Divergence (MACD) for EXEL just turned positive on August 15, 2025. Looking at past instances where EXEL's MACD turned positive, the stock continued to rise in of 45 cases over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where EXEL advanced for three days, in of 310 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 281 cases where EXEL Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The Stochastic Oscillator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where EXEL declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

EXEL broke above its upper Bollinger Band on September 11, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock slightly better than average.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. EXEL’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.165) is normal, around the industry mean (20.594). P/E Ratio (18.755) is within average values for comparable stocks, (53.282). Projected Growth (PEG Ratio) (2.618) is also within normal values, averaging (2.156). Dividend Yield (0.000) settles around the average of (0.044) among similar stocks. P/S Ratio (5.063) is also within normal values, averaging (342.112).

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to slightly better than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

View a ticker or compare two or three
EXEL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published Earnings

EXEL is expected to report earnings to fall 9.05% to 68 cents per share on November 04

Exelixis EXEL Stock Earnings Reports
Q3'25
Est.
$0.68
Q2'25
Beat
by $0.11
Q1'25
Beat
by $0.25
Q4'24
Beat
by $0.16
Q3'24
Beat
by $0.13
The last earnings report on July 28 showed earnings per share of 75 cents, beating the estimate of 63 cents. With 239.15K shares outstanding, the current market capitalization sits at 10.50B.
A.I. Advisor
published General Information

General Information

a developer of small molecule therapies for the treatment of cancer

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
1851 Harbor Bay Parkway
Phone
+1 650 837-7000
Employees
1310
Web
https://www.exelixis.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
IBHF23.380.03
+0.13%
iShares iBonds 2026 Term HY & Inc ETF
EURUSD1.17N/A
N/A
Euro - United States Dollar
AUDHKD5.17N/A
N/A
Australian Dollar - Hong Kong Dollar
CHFHKD9.76N/A
N/A
Switzerland Franc - Hong Kong Dollar
NZDCAD0.82N/A
N/A
New Zealand Dollar - Canadian Dollar

EXEL and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, EXEL has been loosely correlated with JAZZ. These tickers have moved in lockstep 35% of the time. This A.I.-generated data suggests there is some statistical probability that if EXEL jumps, then JAZZ could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To EXEL
1D Price
Change %
EXEL100%
-0.36%
JAZZ - EXEL
35%
Loosely correlated
-0.75%
TECH - EXEL
33%
Poorly correlated
+0.70%
MRSN - EXEL
32%
Poorly correlated
+0.42%
ORMP - EXEL
32%
Poorly correlated
-3.73%
AXON - EXEL
31%
Poorly correlated
+0.62%
More